Jun 2026 (Q3 FY26) — Aug 14, 2026
Outlook Therapeutics Q3 FY26 — FDA Approval of LYTENAVA and U.S. Commercial Launch Preparations
Read the full callOutlook Therapeutics (OTLK) earnings
- Jun 2026
- Jun 2026 (Q3 FY26)
- Sep 2025
Outlook Therapeutics earnings: last reported Fri, 14 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -20.3 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$0.49 0.00% · $0
Performance −62.6% 1Y
1Y: $1.31 on 17 Oct 2025 → $0.49. High $2.47 (16 Dec 2025), low $0.2 (24 Mar 2026).
- Previous close
- $0.49
- 52-week range
- $0.2 – $2.47
- One year
- −66.89%
Overview
- Symbol
- OTLK
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Outlook Therapeutics earnings calls (OTLK)
Financials
What the filings say
Net profit, year on year: −1% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | — | — | — | 2 | — | — | — | — |
| Operating profit | -23 | -22 | -12 | -16 | -17 | -13 | -14 | -11 |
| Operating margin | — | — | — | −1046.2% | — | — | — | — |
| Interest | 0 | — | — | — | — | — | — | — |
| Profit before tax | 6 | — | -46 | -20 | -15 | — | -4 | -20 |
| Tax rate | 0.0% | — | −0.0% | — | 10.5% | — | — | — |
| Net profit | 6 | 17 | -46 | -20 | -13 | -23 | -4 | -20 |
| EPS ($ per share) | — | 0.72 | -1.50 | -0.55 | — | -0.38 | -0.05 | -0.15 |
| Line item | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 1 | 2 | 2 | 0 | 0 | 1 |
| Reserves | -216 | -254 | -290 | -343 | -409 | -468 | -543 | -606 |
| Total liabilities | 43 | 28 | 17 | 18 | 20 | 47 | 102 | 51 |
| Fixed assets | 18 | 3 | 0 | 0 | — | — | — | — |
| Total assets | 22 | 17 | 20 | 23 | 29 | 32 | 29 | 19 |
| Line item | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -33 | -32 | -32 | -54 | -57 | -43 | -69 | -52 |
| Cash from investing | -3 | -0 | -1 | — | — | — | — | — |
| Cash from financing | 34 | 39 | 37 | 56 | 60 | 49 | 60 | 45 |
| Net cash flow | -1 | 6 | 5 | 2 | 3 | 6 | -8 | -7 |
| Capital expenditure | -3 | -0 | — | — | — | — | — | — |
| Free cash flow | -36 | -33 | — | — | — | — | — | — |
Insider filings
10 filings between May 26, 2026 and Aug 14, 2026.
Open market
decisions to buy or sellPurchases
$7.87M
10 purchases by 7 insiders
Sales
None
No insider sold shares.
Some filings report no price, so the dollar figures above are a floor, not a total.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Sukhtian Ghiath M. | $7.50M | — | Aug 12, 2026 |
| HILZINGER KURT J | $176.5K | — | May 26, 2026 |
| Sukhtian Faisal Ghiath | $150.0K | — | Jul 29, 2026 |
| Haddadin Yezan Munther | $39.1K | — | Jun 2, 2026 |
| THURMAN RANDY H | $2.1K | — | May 26, 2026 |
| KENYON LAWRENCE A | $0 | — | Aug 14, 2026 |
| Jahr Robert Charles | $0 | — | Aug 14, 2026 |
Latest filings (13)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 14, 2026 | Jahr Robert Charles Chief Executive Officer | Purchase | 151,515 | — |
| Aug 14, 2026 | KENYON LAWRENCE A Chief Financial Officer | Purchase | 101,010 | — |
| Aug 12, 2026 | Sukhtian Ghiath M. Director | Purchase | 2,525,252 | $2.50M |
| Jul 29, 2026 | Sukhtian Faisal Ghiath Director | Purchase | 95,398 | $100.0K |
| Jun 2, 2026 | Haddadin Yezan Munther Director | Purchase | 29,000 | $24.1K |
| May 28, 2026 | Sukhtian Ghiath M. Director | Purchase | 8,539,709 | $5.00M |
| May 27, 2026 | Sukhtian Faisal Ghiath Director | Purchase | 122,174 | $50.0K |
| May 26, 2026 | HILZINGER KURT J Director | Purchase | 400,000 | $176.5K |
| May 26, 2026 | THURMAN RANDY H Director | Purchase | 5,000 | $2.1K |
| May 26, 2026 | Haddadin Yezan Munther Director | Purchase | 34,000 | $15.0K |
| May 27, 2025 | Sukhtian Ghiath M. Director | Award | 4,285,714 | $6.00M |
| Jan 17, 2025 | Sukhtian Ghiath M. Director | Option exercise | 3,458,571 | $8.68M |
| Sep 26, 2024 | KENYON LAWRENCE A Chief Financial Officer | Purchase | 5,000 | $28.4K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Outlook Therapeutics, Inc.
Free account. Everything above stays public.
Write why you follow Outlook Therapeutics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading